Oncopeptides AB   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Stockholm Sweden (2000)

Organization Overview

First Clinical Trial
2013
NCT01897714
First Marketed Drug
2021
melphalan-flufenamide
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Oncopeptides AB | ONCOPEPTIDES AB | Oncopeptides AB, Stockholm, Sweden